1. Haemolytic activity corresponding to that of the first component of complement (Cl) was synthesized and secreted by all nine human fibroblast cell lines examined. No activity was found in the culture media ofa variety of other human cell lines. 2. The component-Cl haemolytic activity secreted by the fibroblast lines behaved in an identical manner, in most respects, with that of the component-Cl haemolytic activity of human serum. The component-Cl haemolytic activity secreted by fibroblasts, however, was less susceptible to inhibition by rabbit fragment F(ab)2 anti-(human subcomponent Cl q) than was the component-Cl haemolytic activity of human serum. 3. Biosynthesis of fibroblast component-Cl haemolytic activity was inhibited by the presence of cycloheximide and regained on its removal. 4. Incorporation of radioactivity into proteins secreted by the fibroblasts and release of component-Cl haemolytic activity by the fibroblasts both increased in a linear manner until several days after the cultures had reached a state of confluent growth. 5. Radioactivity was incorporated into subcomponents Clq, Clr and Cls, asjudged by the formation of specific immunoprecipitates and by absorption with immune aggregates. 6. The immunoprecipitates formed by using antisera against subcompoqats Clr and Cls were run on polyacrylamide gels in sodium dodecyl sulphate, and thi provided convincing physiochemical evidence for the biosynthesis of these subcoinponents de novo. 7. The results obtained with immunoprecipitates formed by using anti-(subcomponent Clq) suggest that subcomponent Clq may be synthesized and secreted by fibroblast cell lines in vitro, in a form with a higher molecular weight than that of subcomponent Clq which is isolated by conventional techniques of protein fractqpation from fresh serum.
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The first component of complement (Cl) is a Ca2+-dependent complex composed of the three subcomponents Clq, Clr and Cls (Lepow et al., 1963; Gigli et al., 1976) . All three subcomponents have been reported to be synthesized, as estimated by the formation of component-Cl haemolytic activity, by the columnar cells of the small and large intestine in the guinea pig (Colten et al., 1966 (Colten et al., , 1968 . Other studies, using immunochemical techniques, have suggested that human and monkey subcomponent Clq may be produced by a variety of tissues such as the liver, spleen, bone marrow, lung and macrophages (Stecher et al., 1967) . In another study, Day et al. (1970) presented evidence that, in the pig, non-intestinal tissues, particularly those rich in lymphoid cells, produced material antigenically similar to subcomponent Clq. Bing et al. (1975) have shown that long-term primary suspension cultures of normal human colon, adenocarcinoma of the colon and transitional epithelial cells of the urogenital tract synthesized the entire component-Cl complex, as judged by haemolytic activity and, in certain cases, by immunochemical techniques. These latter Vol. 167 results are considered to be consistent with the original findings by Colten et al. (1966 Colten et al. ( , 1968 ) (see Colten, 1976 , for review), since it is believed that epithelial cells of the urogenital tract and colon may be of common origin. Al-Adnani & McGee (1976) have shown, by immunoperoxidase and immunoprecipitation procedures, that material antigenically similar to subcomponent Clq is synthesized and secreted by human and rat fibroblast cell lines. However, Bing et al. (1975) found no evidence for synthesis of the component-Cl complex in the one fibroblast line that they examined. In the present paper we report the biosynthesis of component-Cl haemolytic activity by nine fibroblast cell lines and the incorporation of radioactivity into material that behaves immunochemically and physiochemically in a similar fashion to subcomponents Clr and Cls. Evidence was obtained that subcomponent Clq may be synthesized by fibroblasts in culture and secreted in a form with an apparently higher molecular weight than that of subcomponent Cl q isolated from normal human serum.
Materials and Methods

Cell lines used
Nine human fibroblast cultures were tested for the ability to synthesize component-Cl haemolytic activity. Of these, eight were primary explants from skin biopsies or lung tissue. Three were from foetal tissue and five from adult tissue. The ages of the cells, as shown in Table 1 Culture conditions used to grow cells Cells were grown at 37°C for several generations in RMPI/1640 medium (Gibco Bio-Cult, Paisley, Renfrewshire, Scotland, U.K.) with 10 % (v/v) foetal calf serum plus penicillin (100 units/ml) and streptomycin (100,ug/ml). For measurement of component-Cl haemolytic activity, and for the radioisotope-labelling experiments, the cells were transferred to the same medium with 10% (v/v) heatinactivated foetal calf serum. Foetal calf serum was obtained from Gibco Bio-Cult and was inactivated by heating at 56°C for 30min, which destroys the bovine component-Cl haemolytic activity. Three batches of foetal calf serum were tested. In one of these, all the fibroblasts tested gave approx. 10-15-fold higher amounts of component-Cl haemolytic activity. Fibroblasts grown in RPMI1640 medium made 20% (v/v) with respect to inactivated human AB serum (Blood Transfusion Centre, Oxford, U.K.) gave low activity.
Lymphocytes from peripheral blood were separated on a Ficoll/Triosil gradient (B0yum, 1968) and cultured in RPMI/1640 medium made 20% (v/v) with inactivated human AB serum and 1% (w/v) with phytohaemagglutinin.
Fibroblasts that were growing well had a doubling time of about 24h, i.e. they reached confluency at days 3 and 4 of the experiment and gave the very tightly packed monolayer typical of fibroblasts in culture. Fibroblasts that appeared to be reaching senescence had longer doubling times and never appeared to be very tightly packed. These cells appeared to have stopped producing detectable amounts of component-Cl haemolytic activity.
The number of cells in the fibroblast cultures was approx. 2 x 106 when confluent, and about 5 X 106 for the D98/AH2 cell line. The lymphocyte culture was from 5 ml of blood and contained about 6 x 106 lymphocytes in 60ml of medium. The lymphoid lines were grown in suspension to about Table 1 . Cell lines examinedfor the ability to synthesize and secrete component-Cl haemolytic activity Full experimental details of the culture conditions used to grow the cells and a description of the assay ofcomponent-Cl haemolytic activity are given in the text. All the fibroblast lines tested released component-Cl haemolytic activity into the culture medium, whereas the media of all the non-fibroblast lines showed no detectable component-Cl haemolytic activity in the assay used. Most cell lines not given a reference were developed in the Genetics Laboratory, University of Oxford, Oxford, U.K., where they are in routine use. 
Inhibition of biosynthesis of component-Cl haemolytic activity by cycloheximide Two identical cultures of DUV fibroblasts, grown in parallel, were monitored for component-Cl haemolytic activity. On day 6 the medium was removed and medium containing cycloheximide (2001ug/ml) was added to each culture. On day 8 the cycloheximide was removed from one bottle by removing the medium and washing the monolayer with fresh medium. Fresh medium was then added back to this bottle and monitoring of the component-Cl haemolytic activity released into the culture media of both cultures was continued (Fig. 5) .
Assay of component-Cl haemolytic activity in culture media Preparation of the reagents and buffers used in the haemolytic assays was performed as described by Reid et al. (1977) . Dilutions of the cell culture medium (0.5ml), made in veronal-buffered saline assay medium, were incubated with EAC4 cells (0.5ml, 1 x l0I cells/ml) at 30°C for 20min, then ice-cold veronal-buffered saline assay medium (1 .Oml) was added and the cells were spun down at lOOOg for 10min. The cell pellet was resuspended in assay buffer (l.Oml) and incubated at 30°C for 60min, then component C2 (0.5ml, 200 effective molecules/ml) was added and the mixture incubated at 30°C for 15min. EDTA buffer (0.5ml), pH7.4, was then added, and finally the reagent C-EDTA (1.Oml) was added and incubation continued for 1h at 37°C. The degree of lysis was determined by reading the A412 of the IOOOg supernatant after addition of4.5 ml of 0.15M-NaCl,
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Antisera to subcomponents Clq, Clr and CTs Rabbit anti-(human subcomponent Clq) was prepared as described by Reid et al. (1972) . Antisera to human subcomponents Cir and CTs were provided by Dr. R. B. Sim and were prepared as described by Sim et al. (1977) .
IgG* and fragment F(ab')2 were prepared from normal rabbit serum and rabbit anti-(human subcomponent Clq) serum as described by Reid (1971) . Liquid-scintillation counting of radioactivity in suspensions and in polyacrylamide-gel slices or gel slice (1.2-1.5mm) was placed in liquid-scintillation vials and 1.Oml of a solution of water/NCS tissue solubilizer (1:9, v/v) added. Vials were incubated at 50°C for 2h; then, after cooling, lOml of toluene containing 0.5 % (w/v) PPO (2,5-diphenyloxazole) and0.03 % (w/v) dimethyl-POPOP [1,4-bis-(4-methyl-5-phenyloxazol-2-yl)benzene] was added to each vial. Samples were counted for radioactivity in an LKB-Wallac 1210 Ultrobeta counter. Polyacrylamide-gel electrophoresis in sodium dodecyl sulphate Polyacrylamide-gel electrophoresis in SDS was performed as described by Fairbanks et al. (1971) . Preparation of human subcomponent Clq Human subcomponent Clq was prepared as described by Reid (1974) .
Immunoprecipitation, or absorption with immune aggregates, of the Cl subcomponents from radioactively labelledfibroblast culture media (1) Immunoprecipitation of subcomponent Clq. A solution of carrier subcomponent Clq (0.3-0.6ml, lOOO1ug/ml) was added to the culture medium (20-30ml) obtained from radioactive-labelling experiments. The mixture was made 10mm with respect to EDTA, then it was concentrated to approx. 1.8ml in an Amicon Diaflo lOml cell by using a PM-10 membrane. The concentrate was mixed with enough heat-inactivated rabbit anti-(human subcomponent Clq) to precipitate all the unlabelled carrier subcomponent Clq added. [The rabbit anti-(human subcomponent Clq) had been dialysed extensively against lOmM-EDTA/15OmM-NaCI, pH7.4, before use.] The mixture of concentrate plus antiserum was incubated at 37°C for 2h, then at 4°C for 16h. The immunoprecipitate formed was washed with 5 x 0.5ml ofice-cold lOmM-EDTA/150mM-NaCl, pH7.4. Samples of this subcomponent-Clq immunoprecipitate were then taken for measurement of radioactivity or for electrophoresis on polyacrylamide gels in the presence of SDS.
(2) Immunoprecipitation of the proenzyme forms of subcomponents Clr and Cl s. To the first supernatant obtained after centrifuging down (2000g, 15 min) the subcomponent-Clq immunoprecipitate, human serum (l.Oml) was added (the human serum had been dialysed against lOmM-EDTA/150mM-NaCI, pH7.4, and contained approx. 60,pg of each ofthe proenzyme forms of subcomponents CIr and Cls). Then enough rabbit anti-(human subcomponent CTr) and rabbit anti-(human subcomponent CTs) was added to precipitate all the unlabelled carrier proenzyme forms of subcomponents Clr and Cls over 16h at 4°C. The subcomponent Clq in the human serum was precipitated at this step also by virtue of its binding affinity for immune aggregates. The immunoprecipitate was allowed to form and was washed in exactly the same manner as for the subcomponentClq immunoprecipitate.
(3) Immunoprecipitation of the activated forms of subcomponents Clr and Cls. Concentrated radioactively labelled fibroblast-culture medium (1.8ml) was incubated with ovalbumin-anti-ovalbumin immune aggregates (0.15 ml, 1.77mg of antibodyantigen aggregate/ml; the ratio, by wt., of antibody to antigen was 9.4:1.0) at 37°C for 2h and then made 10mm with respect to EDTA. The immune aggregates were removed by centrifugation (2000g, 15min) . To the supernatant, human serum (1.Oml), or a partially purified activated CT preparation (1.Oml, containing 50g each of the activated forms of subcomponents Clr and Cls), was added. The immunoprecipitation and washing procedures then used were identical with those described above, except that all solutions were made 5mM with respect to CaCI2 and a 2h incubation at 37°C was included before the immunoprecipitation step for 16h at 4°C.
(4) Binding of subcomponent Clq to immune aggregates. A solution of carrier subcomponent Clq (0.2 ml, IOOO,ug/ml) was addedto radioactively labelled fibroblast culture medium (20-30 ml). The mixture was made 10mM with respect to EDTA and then concentrated to 1.8 ml in an Amicon Diaflo lOml cell with a PM-10 membrane. Immune aggregates composed of ovalbumin and anti-ovalbumin (0.3 ml, 1.77 mg of antibody aggregate/ml) were added to the concentrated labelled medium and incubated at 30°C for 30min and then at 4°C for 16h. The suspension was centrifuged (2000g, 15min) and the precipitate washed with 5 x 0.5 ml of ice-cold 10mM-EDTA/l50mM-NaCI, pH7.4. Samples of this precipitate were taken for radioactivity counting and SDS/polyacrylamide-gel electrophoresis.
Binding of radioactively labelled material, from fibroblast culture medium, to antibody-sensitized erythrocytes Radioactively labelled material from fibroblast culture medium (20ml) was concentrated to 1.6ml.
Samples of the concentrate (0.1 5ml) were added to antibody-sensitized cells (O.5 ml, 2 x 108 cells/ml) or unsensitized cells (0.5 ml, 2 x 108 cells/ml). The mixture was incubated at 30°C for 30min, then spun down (lOOOg, 10min). The supernatant was kept for assay of component-Cl haemolytic activity, and the pellet was resuspended in assay buffer (0.75ml) and then extensively washed (with 7xO.75ml) with assay buffer. After the final wash the packed cells were dissolved in NCS tissue solubilizer (l.Oml), and the amount of bound radioactivity was determined.
Inhibition offibroblast andhuman serum component-Cl haemolytic activity by rabbit fragment F(ab')2 anti-(human subcomponent Clq) Dilutions (0.5 ml, 8 x 108 effective component-Cl molecules/ml) of fibroblast medium, from a culture that had been growing for 9 days, were incubated at 30°C for 14min with increasing dilutions (1:10 to 1:20480) of rabbit fragment F(ab')2 anti-(human subcomponent Clq) (0.5ml, stock solution 1.21 mg/ml) or normal rabbit fragment F(ab')2 (0.5 ml, stock solution 2.50mg/ml). Dilutions (0.5 ml, 3.6 x IO' effective component-Cl molecules/ml) of normal human serum in place of fibroblast medium were treated in the same manner. EAC4 cells (0.5 ml, 1 x 108 cells/ml) were then added and the assay for component-Cl haemolytic activity was carried out as described above.
Binding offibroblast and human serum component-Cl haemolytic activity bypreformedimmune aggregates Dilutions of fibroblast medium (0.5nml, 2.9x108 effective component-Cl molecules/ml) or human serum (0.5ml, 1.6x 108 effective component-Cl molecules/ml) were incubated at 30°C for 15min with increasing dilutions (1: 5-1:20480) of an antibodyantigen suspension (0.5ml, stock solution 4.65mg of antibody aggregate/ml). EAC4 cells (0.5ml, 1 x 108 cells/ml) were then added, and the assay for component-Cl haemolytic activity was carried out as described above.
Results
Cell lines examined for the ability to synthesize and secrete component-Cl haemolytic activity into the culture medium
All nine human fibroblast cell lines listed in Table I synthesized and released component-Cl haemolytic activity to approximately the same amount when grown in medium containing the same batch of heatinactivated foetal calf serum. As shown in Fig. 1 Vol. 167 obtained. The value obtained in Fig. 2 for the 7-day DUV culture medium was 2.3 x 109 effective molecules/mI. The starting culture medium and the culture media from other, non-fibroblast, cell lines (Table 1) all gave negative values when tested for component-Cl haemolytic activity. This showed that, if these cells did synthesize the component-Cl complex, then they did not release it into the culture medium, or, if it was released, it was present at an amount at which it could not be detected by the haemolytic assay used. The number of cells per ml in the culture media of these non-fibroblast cell lines was approximately the same as, or greater than, that obtained in the fibroblast cultures.
In the radioactive-labelling studies only three of the fibroblast cell lines were used, the DUV, HM and LNSV-40 lines, which were all derived from adult skin. LNSV-40 fibroblasts are an SV-40-virustransformed line. In view of the apparent dependence of the magnitude of the release of componentCl haemolytic activity, by the fibroblasts, on the batch of foetal calf serum used, and perhaps other experimental factors, the cultures were routinely checked for adequate synthesis of component-Cl haemolytic activity after 2-3 days' growth, before they were used for radioactive-labelling experiments. Recent experiments have indicated that variability in the amounts of component-Cl haemolytic activity found in fibroblast culture medium is primarily due to either lack of subcomponent-Clq synthesis and secretion or inactivation of subcomponent Clq.
In these experiments addition of purified human subcomponent Clq (0.5ml, 50-200ng/ml) to fibroblast culture medium (0.5 ml dilutions) showing very low component-Cl haemolytic activity (less than 1 x 108 effective molecules/ml) resulted in the generation of component-Cl haemolytic activity of the order of 1 x 109-5 x 109 effective molecules/ml.
Similarities between the component-Cl haemolytic activity released by human fibroblasts and the component-Cl haemolytic activity found in human serum The presence of a component-Cl haemolytic activity in the culture media of human fibroblasts which appears identical with that found in human serum was shown in four ways.
(1) Specificity in the assay for component-Cl haemolytic activity. In the lysis of sheep erythrocytes there was an absolute requirement for antibody to sheep erythrocytes, components C4, C2 and components C3-C9 in addition to the activity from the fibroblast culture medium ( Table 2 ). The component Cl haemolytic activity found in the fibroblast culture medium also displayed a specific binding role, since it was efficiently bound on to erythrocytes sensitized with antibody, but not to unsensitized erythrocytes (Table 2) . Fibroblast medium (il) 62.5 Fig. 2 . Titration of the component-Cl haemolytic activity released into fibroblast culture medium Unconcentrated fibroblast culture medium (0.5 ml) from a 7-day culture of DUV fibroblasts was used in a titration of the number of effective, or functionally active, component-Cl molecules. y is the percentage lysis of the erythrocytes used in the assay, and -ln(I -y) is plotted against 2-fold dilutions of the culture medium. The dilution at which -In (l-y)= 1 is that at which an average of one haemolytically effective molecule of component Cl is offered per erythrocyte used in the assay (0.5ml, 1 x108 cells/ml). No component-Cl haemolytic activity was found in culture medium that was incubated without fibroblasts. Full details of the assay used for the determination of component-Cl haemolytic activity are given in the text. (Table 2 ) and also was inhibited by 2nM-di-isopropyl phosphorofluoridate after it had been activated by complexing with cellbound antibody. (3) Fixation by immune aggregates. Both fibroblast component-Cl haemolytic activity and normal human serum component-Cl haemolytic activity were readily fixed by preformed immune aggregates made from rabbit anti-ovalbumin and ovalbumin (Fig. 3) . The degree of fixation of samples of fibroblast, and human serum component-Cl haemolytic activity, which had approximately equivalent Cl haemolytic titres, was almost identical (Fig. 3) . This suggests that both fibroblast and human serum component-Cl haemolytic activity are bound to immune complexes by the same mechanism. Antibody-antigen aggregate added (pg) Fig. 3 . Inhibition offibroblast andhuran serum componentCl haemolytic activity by immune aggregates Samples (0.5ml) of fibroblast culture medium (2.9 x 108 effective component-Cl molecules/ml) and samples (0.5ml) of human serum (1.6 x 108 effective component-Cl molecules/ml) were incubated with increasing dilutions of preformed rabbit antiovalbumin immune aggregates and then assayed for the presence of component-Cl haemolytic activity. Full experimental details are given in the text. 0, Percentage inhibition of lysis of the sensitized erythrocytes used in the component-Cl haemolytic assay produced by the addition of immune aggregates to fibroblast culture medium; A, percentage inhibition of lysis of sensitized erythrocytes used in the component-Cl haemolytic assay produced by the addition of immune aggregates to human serum.
were inactivated by rabbit fragment F(ab')2 anti-(human subcomponent Cl q) (Fig. 4) under conditions where no inactivation by equivalent concentrations of normal rabbit fragment F(ab')2 took place (Fig. 4) . However, the component-Cl haemolytic activity from normal human serum was far more readilyinactivated than was the fibroblast componentCl haemolytic activity by the rabbit fragment F(ab')2 anti-(human subcomponent Clq) (Fig. 4) even when over four times the amount of component-Cl activity found in human serum, relative to the component-Cl activity secreted by fibroblasts, was used.
Evidence for synthesis de novo of component-Cl haemolytic activity byfibroblasts
As shown in Fig. 1 -fibroblast component-Cl haemolytic activity was released into the culture medium, in a linear manner, until at least 3-4 days after the cells had reached confluent growth. When fibroblasts were taken after 6 days of culture and were washed and resuspended in fresh culture medium, containing cycloheximide, only very low component-Cl haemolytic activity could be detected (Fig. 5) . However, after removal of the culture medium containing cycloheximide and replacing it with fresh culture medium, the rate of release of component-Cl haemolytic activity from the fibroblasts approached that observed during the first 6 days of culture (Fig. 5) . Vol. 167
Evidence that protein biosynthesis de novo was taking place was provided by the incorporation of radioactivity into trichloroacetic acid-precipitable protein, in a linear manner, for up to 3-4 days after the cells had reached confluence (Fig. 1) .
Incorporation of radioactivity into proteins released from fibroblasts that have similar functional and physiochemical characteristics to the subcomponents of component Cl
(1) Binding of radioactivity from fibroblast culture medium to erythrocytes coated with antibody. The amount of radioactivity bound to antibody-sensitized erythrocytes when they were incubated with radioactively labelled fibroblast medium, under the conditions described in the Materials and Methods section, was 1104 Fragment F(ab')2 anti-(subcomponent Clq) or normal fragment F(ab')2 (Ug) Fig. 4 . Inhibition offibroblast and human serum componentCl haemolytic activity by rabbit fragment F(ab')2 anti-(human subcomponent Cl q) Samples (0.5 ml) of fibroblast culture medium (8x108 effective component-Cl molecules/ml) and samples (0.5ml) of human serum (3.6 x I09 effective component-Cl molecules/ml) were incubated with increasing dilutions of rabbit fragment F(ab')2 anti-(human subcomponent Clq) or normal rabbit fragment F(ab')2, and then assayed for component-Cl haemolytic activity. Full experimental details are given in the text. 0, Percentage inhibition of lysis of sensitized erythrocytes used in the component-Cl haemolytic assay, produced by the addition of rabbit fragment F(ab')2 anti-(human subcomponent Clq) to fibroblast culture medium; [O, percentage inhibition of lysis of sensitized erythrocytes used in the component-Cl haemolytic assay, produced by the addition of rabbit fragment F(ab')2 anti-(human subcomponent Clq) to human serum; a, percentage inhibition of lysis of sensitized erythrocytes used in the component-Cl haemolytic assay, produced by the addition of normal rabbit fragmnent F(ab')2 to fibroblast culture medium or human serum. The labelling patterns found on SDS/polyacrylamide gels were similar when the patterns obtained for immunoprecipitates made from 3 h and 72h radioactively labelled media were compared.
When radioactively labelled immunoprecipitates made by using anti-(subcomponent Clq) were run on 5.6 % polyacrylamide gels in SDS without reduction of the disulphide bonds, no major radioactive peaks entered the gel. The unlabelled carrier subcomponent Clq readily entered the gel and was found in the expected positions [two peaks of apparent mol.wts. 69000 and 54000 in a ratio of 2:1, w/w; the molecular weights were calculated as described by Reid et al. (1972) and Reid & Porter (1976)] (Fig. 6a) . When the non-reduced labelled subcomponent-Clq immunoprecipitates were run on 4 % polyacrylamide gels in SDS, no major radioactive peaks were found in the sliced gel. When radioactively labelled subcomponent-Clq immunoprecipitates were reduced and alkylated and run on 5.6 % polyacrylamide gels, most preparations showed either two major radioactive peaks with apparent mol.wts. of 47000 and 42000, or one major peak of apparent mol.wt. 47000, which had a distinct 'shoulder' in the lower-molecular-weight region (Fig. 6b) . These radioactive peaks clearly separated from the heavy chain ofIgG (52000 apparent mol.wt.) or the A chain ofsubcomponent Clq (34000 apparent mol.wt. in polyacrylamide gels run in SDS). A third, smaller, peak of radioactivity (22000 apparent mol.wt.) was usually observed, and this was separated from the C chain of subcomponent Cl q, which has an apparent mol.wt. of 27000.
The profiles of 5.6% polyacrylamide gels run in SDS of immunoprecipitates made by using a mixture of antisera to subcomponents Clr and Cls 1977 immunoprecipitates labelled with radioactivity Imnmunoprecipitates were obtained from radioactively labelled fibroblast culture medium after addition of carrier subcomponents Clr and Cls and antisera to these subcomponents. Subcomponent Clq is also found in these immunoprecipitates, for the reasons discussed in the text. The samples were run on 5.6% polyacrylamide gels in the presence of SDS. Figs. 7(a) and 7(b) . When the immunoprecipitation was performed in the presence of EDTA, and at 4°C, the subcomponents were not activated and accordingly displayed the very characteristic banding patterns that have been observed when the non-reduced (Fig. 7a ) and reduced and alkylated (Fig. 7b) proenzyme forms of the subcomponents are run on polyacrylamide gels in SDS (Gigli et al., 1976) . The peaks of radioactivity found in the unreduced labelled sample were exactly coincident with the unreduced subcomponent Clr (apparent mol.wt. 98 000) and unreduced subcomponent Cls (apparent mol.wt. 92000) (Fig. 7a) . A single peak of radioactivity was found in the reduced and alkylated sample that ran with the marker reduced and alkylated proenzyme forms of subcomponents Clr and Cls, which both have an apparent mol.wt. of 83000 (Fig. 7b) .
When immunoprecipitates of subcomponents Clr and Cls were made from culture medium that had been incubated at 37°C with antibody-antigen aggregates, and then made lOmm with respect to EDTA, the major radioactive peaks that entered the 5.6 % polyacrylamide gel run in SDS followed the expected patterns obtained with the activated forms of subcomponents Clr and Cls. Under these conditions unreduced subcomponents CTr and Cls have apparent mol.wts. of 107000 and 92000 respectively . Reduction of subcomponent CTr yields chains with apparent mol.wts. of 58000 and 36000, whereas reduced subcomponent CTs yields chains with apparent mol.wts. of 58000 and 29000 . When the carrier subcomponents Clr and Cls were added in the form of human serum and activation was subsequently brought about during immunoprecipitation, then complexes between the inhibitor of the activated form of component Cl and subcomponents CTr and CTs were formed. These complexes are stable in polyacrylamide gels run in SDS (Harpel & Cooper, 1975) , and the major radioactive peaks in these immunoprecipitates were coincident with the subcomponent-CT inhibitor peaks.
When labelled medium was mixed with preformed anti-ovalbumin-albumin aggregates, in the presence of EDTA, radioactivity [amounting to approx. 60 % of the radioactivity bound in anti-(subcomponent Clq) immunoprecipitates] was bound to the aggregates. When the labelled immune aggregates were reduced and alkylated and then examined on 5.6% polyacrylamide gels, run in SDS, there were three radioactively labelled peaks located in the 48000-38000 apparent-mol.wt. region, a labelled peak in the 155000 apparent-mol.wt. region and another labelled peak of very much higher molecular weight, which had just entered the top of Polyacrylamide-gel electrophoresis in SDS of reduced and alkylated radioactively labelled immune aggregates Preformed immune aggregates of anti-ovalbumin and ovalbumin were incubated with radioactively labelled fibroblast culture medium in the presence of EDTA. The radioactivity bound to the immune aggregates was examined, after reduction and alkylation, on a 5.6% polyacrylamide gel run in SDS. Full experimental details are given in the text. The marker proteins whose position is indicated on the scale ofapparent molecular weights are: 155 000, IgG (added after reduction and alkylation of the sample); 52000, heavy chain of IgG; 23500, light chain of IgG. Vol. 167 the gel (Fig. 8) . Without reduction and alkylation of the labelled immune aggregates, no major radioactively labelled peaks were seen when the sample was run on polyacrylamide gels in SDS.
Discussion
The results in the present paper clearly demonstrate that human fibroblast cell lines synthesize and secrete a haemolytic activity that is functionally identical in many respects with the component-Cl haemolytic activity found in human serum (Table 2 ; Figs. 2  and 3 ). This activity was found in the culture media of all the human fibroblast cell lines examined and was not detected in the culture media from a number of non-fibroblast cell lines (Table 1) . Since the fibroblast-cell-line cultures are unlikely to contain significant amounts of any other type of cell, it appears probable that a single cell type may synthesize all the subcomponents of the componentCl complex. However, the rate of synthesis and secretion of subcomponents Clr and Cls may be independent of the rate of synthesis and secretion of subcomponent Clq. Thus fibroblast culture media that had unexpectedly low amounts of the component-Cl haemolytic activity appeared to have normal amounts of the Clr and Cls subcomponents and a low subcomponent-Clq value, as judged by the increase in the component-Cl haemolytic activity caused by the addition of purified subcomponent Clq to the media with the low amounts of component-Cl haemolytic activity.
The ability to synthesize component-Cl haemolytic activity appears to be a general property of human fibroblasts and they, under the optimal experimental conditions obtained so far, synthesize and secrete this activity at a rate of approx. 104 effective component-Cl molecules per day in vitro. It is possible that, if this rate of synthesis and secretion takes place in vivo, fibroblasts may be a major source of the component-Cl haemolytic activity found in plasma, since they are one of the most abundant cell types in the body. Al-Adnani & McGee (1976) have shown that rat skin fibroblasts in vitro synthesized material that was antigenically similar to subcomponent Clq. They also presented evidence that this material was synthesized by the rat fibroblasts in vivo, at least in pathological conditions where the fibroblasts were functioning at a much higher rate than normal. Attempts to prepare primary cultures of specialized cell types are often hampered by the tendency of fibroblasts to grow more rapidly than other cells; therefore it appears that care would have to be taken to exclude fibroblasts from a cell culture if a study of the possible biosynthesis of component-Cl haemolytic activity by non-fibroblast cell lines is to be made.
Functionally and physiochemically, the fibroblast cell lines produce proteins that appear to be identical with the Clr and Cls subcomponents found in human serum. On the other hand, the protein synthesized by the fibroblasts that appears to fulfil the role of subcomponent Clq differs in certain respects from the subcomponent Clq found in normal human serum. The principal role of subcomponent Clq, of binding to immune aggregates, appears to be common to the fibroblast subcomponent Clq and subcomponent Clq purified from human serum. This is shown by the fact that the component-Cl haemolytic activity released by fibroblasts binds to erythrocytes sensitized with antibody (Table 2 ) and to insoluble antibody-antigen aggregates (Fig. 3) . The binding, or fixation, of fibroblast component Cl and human serum component Cl appears almost identical in terms of haemolytic units bound per pg of antibody-antigen aggregate (Fig. 3) , which suggests that they are bound by the same mechanism. However, the proposed fibroblast subcomponent Clq differs markedly, in at least two respects, from subcomponent Clq purified from human serum: (1) it appears to react very weakly with antisera prepared against subcomponent Clq purified from human serum (Fig. 4) ; (2) its apparent molecular weight, as judged by polyacrylamide-gel electrophoresis in SDS, is greater than that of purified subcomponent Clq (Figs. 6a, 6b and 8 ).
The interaction between rabbit fragment F(ab')2 anti-(subcomponent Clq) and fibroblast or serum subcomponent Clq was examined by determining the ability of the antibody to inhibit the componentCl haemolytic activity found in fibroblast culture medium or human serum (Fig. 4) . Even when approximately one-fifth the amount of fibroblast component Cl compared with serum component Cl was used (on a haemolytic basis), there was a requirement for 30 times as much antibody to give 95-100% inhibition of the fibroblast component-Cl haemolytic activity compared with that required to give the same degree of inhibition of the serum component-Cl haemolytic activity (Fig. 4) (Figs. 6a, 6b and 8 ) support 1977 the view that fibroblast subcomponent Clq contains peptide extensions in all three of its chains and that these extensions are cross-linked by interchain disulphide bonds. With reduction and alkylation of disulphide bonds, the major portion of the radioactivity precipitated along with the subcomponent-Clq immunoprecipitate (Fig. 6b) , or with immune aggregates in the presence of EDTA (Fig. 8) , was found in polypeptides in the apparent mol.wt. range 48000-42000. The reduced and alkylated A, B and C chains of purified subcomponent Clq behave anomalously on polyacrylamide-gel electrophoresis in SDS, since they have apparent mol.wts. of 34000, 32000 and 28 000 respectively asjudged bythis method (Reid et al., 1972) , whereas their true molecular weights are all in the range 22000-24000 (Reid & Porter, 1976) . Therefore it is possible that the true molecular weights of the polypeptide chains of the radioactively labelled fibroblast material, if it is related to serum subcomponent Clq, may also be lower, i.e. in the range 36000-34000. Gel-filtration studies in 6M-guanidinium chloride should clarify this point. Assuming that the radioactively labelled material is a precursor form of the subcomponent C1 q found in serum, it is possible that such a molecule would have A, B and C chains that were each approx. 12000 higher in molecular weight than that found in the serum form. Since there are 18 chains in subcomponent Clq, this would give an increase in molecular weight of 216000 for the entire molecule. If this is the case, then it would not be surprising that non-reduced fibroblast subcomponent Clq did not enter 5.6% or 4% polyacrylamide gels run in SDS (Fig. 6a) . The presence of only two types of disulphide bond in the proposed extensions to the A, B and C chains (i.e. a B-to-C-type disulphide bond and an A-to-A-type disulphide bond) would yield a molecule of at least 21600+410000 = 626000 molecular weight even under dissociating conditions.
It would not be entirely unexpected for subcomponent Clq to be synthesized as a precursor with disulphide-linked polypeptide extensions, since it is now well established that the threenon-disulphidelinked polypeptide chains of certain collagen molecules are first synthesized as procollagen molecules with disulphide-linked polypeptide extensions at either the N-terminus or C-terminus of their chains (Nowack et al., 1976; Olsen et al., 1976; Byers et al., 1975; Fessler et al., 1975) . Thus subcomponent Clq may show some relationship to collagen in the manner in which it is synthesized, which would be consistent with previous results that show that collagen-like regions are found in the A, B and C chains of subcomponent Clq, and that these regions contain hydroxylated amino acid residues, glycosylated hydroxylysine residues and probably form a typical collagen-like triple-helical structure (Reid, 1974 (Reid, , 1976 Calcott & Muller-Eberhard, 1972; Brodsky-Doyle et al., 1976) .
In conclusion, a component-Cl-like haemolytic activity appears to be synthesized and secreted by human fibroblasts, and material functionally equivalent to each of the subcomponents Clq, Clr and Cls has been found. Identification of newly synthesized radioactively labelled precursor forms of subcomponents Clr and Cls has been made antigenically, by immunoprecipitation, and physiochemically, by electrophoresis on polyacrylamide gels run in SDS. Formal identification of newly synthesized radiolabelled subcomponent-Clq molecules in fibroblast culture media has proved difficult, since antigenically and physiochemically the radioactive material tentatively identified as fibroblast subcomponent Clq appears to differ from the subcomponent Clq found in normal serum. E. S. was supported by the Lalor Foundation and, in part, by the Medical Research Council.
